Related references
Note: Only part of the references are listed.High dose melphalan is an adequate preparative regimen for autologous hematopoietic stem cell transplantation in relapsed/refractory lymphoma
Jose A. Fernandez-Gutierrez et al.
HEMATOLOGY (2022)
Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis
Ga-Young Song et al.
LEUKEMIA & LYMPHOMA (2020)
Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial
Qaiser Bashir et al.
LANCET HAEMATOLOGY (2019)
Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study
Guido Ghilardi et al.
BONE MARROW TRANSPLANTATION (2019)
Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party
Holger W. Auner et al.
HAEMATOLOGICA (2018)
Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party
Holger W. Auner et al.
HAEMATOLOGICA (2018)
Autologous stem cell transplant for multiple myeloma patients 70 years or older
E. Muchtar et al.
BONE MARROW TRANSPLANTATION (2016)
Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study
Laurent Garderet et al.
HAEMATOLOGICA (2016)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study
Laurent Garderet et al.
HAEMATOLOGICA (2016)
High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for De Novo Multiple Myeloma Patients: A Phase II Study
Maurizio Musso et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Fifty Years of Melphalan Use in Hematopoietic Stem Cell Transplantation
Ulas D. Bayraktar et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myelotha: A Matched Comparison to a Melphalan-Only Approach
Margarita Blanes et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Autologous transplant in multiple myeloma with an augmented conditioning protocol
Badran Abu Zaid et al.
LEUKEMIA & LYMPHOMA (2013)
Efficacy and Safety of Busulfan-Based Conditioning Regimens for Multiple Myeloma
Donna Reece et al.
ONCOLOGIST (2013)
Autologous Stem Cell Transplantation with Thiotepa, Busulfan, and Cyclophosphamide (TBC) Conditioning in Patients with CNS Involvement by Non-Hodgkin Lymphoma
Gregory M. Cote et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
Meletios Dimopoulos et al.
BLOOD (2011)
Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma
A Anagnostopoulos et al.
CANCER (2004)
Melphalan versus melphalan plus busulphan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma
R Ria et al.
HEMATOLOGY JOURNAL (2004)
High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma
G Cheng et al.
BONE MARROW TRANSPLANTATION (2003)
Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma
A Shimoni et al.
BONE MARROW TRANSPLANTATION (2001)
Chemistry, pharmacology and pharmacokinetics of N,N′,N-triethylenethiophosphoramide (ThioTEPA)
MJ van Maanen et al.
CANCER TREATMENT REVIEWS (2000)
Share Paper
